October 12, 2022
Novartis unit Sandoz is continuing its fight against the U.S. Food and Drug Administration's decision to give exclusivity to a Sanofi multiple sclerosis drug, saying at the D.C. Circuit that the agency's decision was "legally unsupportable."
July 22, 2022
A Washington, D.C., federal judge has ruled against Novartis unit Sandoz in its suit claiming the U.S. Food and Drug Administration improperly gave exclusivity to a Sanofi multiple sclerosis drug, finding the FDA never approved a main component of the drug as an active ingredient before it did so in the MS product.
March 08, 2021
Novartis unit Sandoz has accused the U.S. Food and Drug Administration of improperly giving exclusivity to a Sanofi multiple sclerosis drug even though its active ingredient was present in an earlier drug.